Business

December 28, 2015 7:07 PM

Chimerix stock sinks after antiviral drug fails

Shares drop 81% after patients in clinical trial die at higher rates than those given placebo

Chimerix says deaths weren’t caused by its drug

Executives hope to continue developing the antiviral

Related content

Suggested for you

Comments

Videos

Today's Market

Nasdaq
Powered by Barchart

Editor's Choice Videos